Bioinformatics analysis

Neowise employs efficient bioinformatics analysis methods, which, in close integration with downstream experimental platforms, provide a continuous driving force for target antigen validation and the discoveyr of antigen-specific TCRs.

Ultra-sensitive TCR discovery

Neowise developed a world-class high-throughput and ultra-sensitive antigen-specific TCR discovery platform, which significantly enhances the efficiency of TCR-based drug development.

Functional validation platform

Neowise utilizes a native antigen presentation system to conduct comprehensive efficacy and safety evaluations of gene-edited T cells, selecting the best TCR molecules for clinical development.

World-leading paired antigen-TCR library

Neowise has accumulated over thousands of tumor-specific antigen - natural TCR pairs, covering more than 100 targets (CAST® library). This is the world's largest known database of its kind, offering boundless possibilities for personalized treatment of solid tumor patients.

The path to precision TCR-T cell therapy

For each patient, Neowise selects the optical TCR from its library that recognizes the targets unique to the patient's tumor, enabling rapid delivery of the most suitable cell therapy product for the patient.